RASA4B Activators
RASA4B Activators are a group of compounds that indirectly enhance the functional activity of RASA4B, a protein involved in the negative regulation of RAS signaling, a critical pathway in cell proliferation, differentiation, and survival. Compounds like Epigallocatechin gallate (EGCG) and Farnesol play a key role in modulating pathways that influence RAS activity. EGCG, by inhibiting the EGFR pathway, and Farnesol, through interference with RAS protein post-translational modification, support RASA4B's function in controlling RAS-mediated signaling. Statins, such as Lovastatin, and specific farnesyltransferase inhibitors like Manumycin A and FTI-277, further contribute to this regulation by affecting RAS protein prenylation, enhancing RASA4B's role in mitigating RAS signaling.
Additionally, compounds that influence downstream effectors of RAS, such as LY294002, a PI3K inhibitor, U0126 and PD98059, both MEK inhibitors, and SCH772984, an ERK inhibitor, indirectly support RASA4B's regulatory function. By modulating these downstream pathways, these compounds enhance RASA4B's ability to control RAS signaling, impacting cellular processes like growth and differentiation. Rapamycin, an mTOR inhibitor, also plays a significant role in this regulatory network by influencing a downstream target of RAS signaling, thus supporting the negative regulatory effect of RASA4B on RAS pathways. Moreover, NSC23766's inhibition of Rac1, a RAS-related GTPase, indirectly augments RASA4B's capacity to manage RAS-related signaling pathways, affecting key cellular functions such as cytoskeletal organization. Collectively, these RASA4B Activators illustrate a multifaceted approach to enhancing RASA4B's activity, reflecting the complex interplay between these compounds and RASA4B in the intricate landscape of cellular signaling and regulation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
Epigallocatechin gallate (EGCG) inhibits the EGFR pathway, which can influence the RAS signaling pathway. By modulating this pathway, EGCG can indirectly enhance RASA4B's function in negatively regulating RAS, thus controlling cell signaling and proliferation. | ||||||
Farnesol | 4602-84-0 | sc-204748 sc-204748A | 50 ml 100 ml | $275.00 $367.00 | 2 | |
Farnesol interferes with the post-translational modification of RAS proteins. This interference can enhance RASA4B's activity in RAS signaling by reducing active RAS levels, thereby influencing cellular processes such as proliferation and differentiation. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $28.00 $88.00 $332.00 | 12 | |
Statins, such as Lovastatin, inhibit HMG-CoA reductase and subsequently affect the prenylation of RAS proteins. This inhibition can indirectly support RASA4B's function in controlling RAS-mediated signaling pathways. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
Sphingosine-1-phosphate (S1P) influences RAS signaling. By modulating RAS activity, S1P can indirectly enhance the negative regulation of RAS by RASA4B, impacting processes such as cell proliferation and apoptosis. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, can indirectly influence RAS signaling. By modulating PI3K, LY294002 may enhance RASA4B's function in the negative regulation of RAS, affecting pathways involved in cell survival and proliferation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK, a downstream effector of RAS. This inhibition can indirectly support RASA4B's role in RAS signaling, particularly in pathways related to cell growth and differentiation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a downstream target of RAS signaling. This inhibition can enhance RASA4B's negative regulatory effect on RAS signaling, influencing pathways like protein synthesis and cell growth. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $148.00 $597.00 | 75 | |
NSC23766 inhibits Rac1, a RAS-related GTPase. By modulating Rac1 activity, NSC23766 can indirectly enhance RASA4B's role in controlling RAS-related signaling pathways, affecting cellular processes like cytoskeletal organization. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits MEK, impacting downstream RAS signaling. This inhibition can indirectly support RASA4B's function in controlling RAS-mediated signaling, particularly in cell growth and differentiation pathways. | ||||||
Farnesyl thiosalicylic acid | 162520-00-5 | sc-205322 sc-205322A | 1 mg 5 mg | $60.00 $80.00 | 15 | |
FTI-277, a farnesyltransferase inhibitor, impacts RAS protein modification. By inhibiting farnesylation, FTI-277 can enhance RASA4B's role in negative regulation of RAS signaling, which is crucial for processes like cellular proliferation and differentiation. | ||||||